Plain-language explanation.
Immunology is the study of the immune system — the body's defence against infection, cancer, and foreign substances. Understanding immunity is foundational to vaccine development, treating autoimmune diseases, cancer immunotherapy, and transplantation medicine.
Core concepts and standard treatment.
Core immunology covers the two arms of immunity: innate immunity (non-specific, rapid — pattern recognition receptors — TLRs; complement system; phagocytes — macrophages, neutrophils; NK cells; inflammation — cytokines: IL-1β, TNF-α, IL-6) and adaptive immunity (specific, slower — T lymphocytes: CD4+ helper T cells — Th1/Th2/Th17/Treg subtypes; CD8+ cytotoxic T cells; B lymphocytes — antibody isotypes IgM/IgG/IgA/IgE; MHC class I and II — antigen presentation). Key concepts: clonal selection, immunological memory (basis of vaccination), and tolerance (self vs non-self).
Deeper theory, debates and edge cases.
Advanced immunology covers tumour immunology and cancer immunotherapy (checkpoint inhibitors — PD-1/PD-L1 — nivolumab, pembrolizumab; CAR-T cells — CD19-targeted tisagenlecleucel; tumour microenvironment — immune evasion; TCR-T cell therapy), autoimmune disease mechanisms (loss of tolerance — central/peripheral; Treg defects; molecular mimicry — rheumatoid arthritis, MS, T1DM; biologics — anti-TNF, anti-IL-17, anti-CD20), mucosal immunology (IgA, gut-associated lymphoid tissue — GALT, Peyer's patches; microbiome-immune crosstalk), and systems immunology (single-cell multi-omics of immune cells — CITE-seq, ATAC-seq; mass cytometry — CyTOF; PBMC profiling).
How it is applied in practice.
At the clinical immunologist and biopharmaceutical scientist level, practitioners contribute to Immunity, Journal of Experimental Medicine, and Nature Immunology; lead translational immunology programmes (PBMC profiling in clinical trials, pharmacodynamic biomarkers); design and interpret immunogenicity assays for biologics (ADA — anti-drug antibody testing; ELISA, ECL assay validation — EMA bioanalytical guidelines); advise MHRA on immuno-oncology drug approvals; run allergy and clinical immunology services (RAST/ImmunoCAP, immunotherapy protocols); and contribute to pandemic vaccine immune response characterisation (T-cell, B-cell, neutralising antibody assays — COVID-19 COV-BOOST, PITCH studies).